Where next for <scp>BTKi</scp> – <scp>BCL2i</scp> combinations in mantle cell lymphoma?

COMMENTARY ON: Wang et al. Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. Br J Haematol (Online ahead of print).

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-06-14
DOI
https://doi.org/10.1111/bjh.70621
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Where next for BTKi – BCL2i combinations in mantle cell lymphoma?

Toby A. Eyre
British Journal of Haematology
Lymphoma Diagnosis and Treatment
article

Where next for BTKi – BCL2i combinations in mantle cell lymphoma?

Toby A. Eyre
article en

Abstract

COMMENTARY ON: Wang et al. Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. Br J Haematol (Online ahead of print).

British Journal of Haematology
Churchill Hospital (GB)
Zero hunger
Openalex Percentile: Top 7%
Lymphoma Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Where next for <scp>BTKi</scp> – <scp>BCL2i</scp> combinations in mantle cell lymphoma? — Toby A. Eyre · British Journal of Haematology (2026) | TGRS Research Map | TGRS